The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
12 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $11,749,474 in first-year total cost, median $1,008,414.
Most frequent study sections
- Special Emphasis Panel[ZCA1 SRB-2 (M1)]12
Most frequent institutions
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2
- BROAD INSTITUTE, INC.1
- COLUMBIA UNIVERSITY HEALTH SCIENCES1
- DANA-FARBER CANCER INST1
- EMORY UNIVERSITY1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2017 | Systematic Identification and Pharmacological Targeting of Tumor Dependencies for Precision Cancer Medicine1U01CA217858-01 | CALIFANO, ANDREA | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $1,164,547 | ZCA1 |
| 2017 | Targeting vulnerabilities of therapy-resistant cancer cell states with small molecules1U01CA217848-01 | SCHREIBER, STUART L | BROAD INSTITUTE, INC., MA | $1,146,075 | ZCA1 |
| 2017 | Integrating targeted and immunotherapy to treat genetically heterogeneous cancers1U01CA217864-01 | BALMAIN, ALLANKRUMMEL, MATTHEW FWEISS, WILLIAM A | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $1,065,613 | ZCA1 |
| 2017 | The Cancer Target Discovery and Development Network at UCSF1U01CA217882-01 | BANDYOPADHYAY, SOURAVBIVONA, TREVER GMCMANUS, MICHAEL TWEISSMAN, JONATHAN S. | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $1,034,211 | ZCA1 |
| 2017 | The Dana-Farber Cancer Institute Cancer Target Discovery and Development Center2U01CA176058-05 | HAHN, WILLIAM C. | DANA-FARBER CANCER INST, MA | $1,027,367 | ZCA1 |
| 2017 | A Rational Systematic Approach to Find Combinations of Pharmacologic and Immune Therapies that Target Identifiable Oncogenic States1U01CA217885-01 | COHEN, EZRAKAUFMAN, DAN S.MESIROV, JILL P.TAMAYO, PABLO | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $1,011,983 | ZCA1 |
| 2017 | Functional Genomic Discovery of Pathway Targeted and Immune Modulatory Therapeutic Combinations in Hematologic Malignancies1U01CA217862-01 | DRUKER, BRIAN JMARGOLIN, ADAM ARNETYNER, JEFFREY WALLACE | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $1,004,845 | ZCA1 |
| 2017 | Organoid-based Discovery of Oncogenic Drivers and Treatment Resistance Mechanisms1U01CA217851-01 | CURTIS, CHRISTINA NJI, HANLEE PKUO, CALVIN J | STANFORD UNIVERSITY, CA | $946,126 | ZCA1 |
| 2017 | Pathway Discovery and Target Validation for Outgrowth of Breast Cancer Metastases1U01CA217846-01 | BADER, JOEL S.EWALD, ANDREW JOSEF | JOHNS HOPKINS UNIVERSITY, MD | $915,166 | ZCA1 |
| 2017 | Personalized cancer models to discover and develop new therapeutic targets.1U01CA217883-01 | KEMP, CHRISTOPHER J | FRED HUTCHINSON CANCER RESEARCH CENTER, WA | $902,672 | ZCA1 |
| 2017 | Systematic discovery of neomorph protein-protein interactions in cancer for oncogenic pathway perturbation1U01CA217875-01 | FU, HAIAN | EMORY UNIVERSITY, GA | $791,318 | ZCA1 |
| 2017 | Integrative bioinformatics and functional characterization of oncogenic driver aberrations in cancer1U01CA217842-01 | MILLS, GORDON B.SCOTT, KENNETH L. | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $739,551 | ZCA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.